Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jan;9(1):5-21.
doi: 10.1177/2040622317738910. Epub 2017 Nov 16.

Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis

Jillian Frieder  1 , Dario Kivelevitch  1 , Alan Menter  2
Affiliations
Review

Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis

Jillian Frieder et al. Ther Adv Chronic Dis. 2018 Jan.

Abstract

Psoriasis is a systemic inflammatory disease associated with numerous comorbidities and a profound impact on patients' quality of life. While its complex immune pathogenesis is still not fully delineated, current evidence supports a fundamental role of the T-helper-17 (TH-17) pathway and its related interleukin-17 (IL-17) cytokine. Thus, new antipsoriatic therapies have been developed to block this key cytokine and its downstream effects. Secukinumab is a fully humanized, monoclonal anti-IL-17A antibody, and the first in its class to be approved by the US Food and Drug Administration for the treatment of moderate to severe plaque psoriasis. It has also been approved for the treatment of active psoriatic arthritis and ankylosing spondylitis. Its clinical efficacy in plaque psoriasis has been well demonstrated in numerous phase II and III clinical trials. In addition, it has shown superiority in clinical trials to current biologic agents including etanercept and ustekinumab, with a safe adverse event profile. In correlation with excellent skin improvements, secukinumab is also associated with significant improvements in health-related quality of life measures. Thus, secukinumab offers the potential for equal, or improved, therapeutic effects compared with other biologics, and is a valuable addition to our current antipsoriatic armamentarium.

Keywords: Cosentyx; biologics; generalized pustular psoriasis; interleukin 17A; palmoplantar psoriasis; psoriasis; psoriatic arthritis; secukinumab.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr Frieder and Dr Kivelevitch have no conflicting interests to disclose. Dr Menter reports grants and honoraria from AbbVie, Allergan, Amgen, Boehringer Ingelheim, Janssen Biotech, Inc., LEO Pharma, Novartis, Pfizer, and Xenoport; grants from Anacor, Celgene, Dermira, Merck, Neothetics, Regeneron, and Symbio/Maruho; and honoraria from Eli-Lily, Galderma, and Vitae, all outside of the submitted work.

Figures

Figure 1.
Figure 1.
The five interleukin-17 receptor (IL-17R) complexes and their corresponding ligands. IL-17B binds to the receptor complex composed of the IL-17RB subunit and an unknown subunit. IL-17A and IL-17F are stimulated by T-helper-17 (TH17) cells and bind to the IL-17RC and IL-17RA receptor complex (not shown: IL-17A/IL-17F heterodimers also bind to this receptor complex). IL-17E (IL-25) binds to the IL-17RB and IL-17RA receptor complex. IL-17C binds to the IL-17RE and IL-17RA receptor complex. The ligand for the IL-17RD and IL-17RA receptor complex is currently unknown. Secukinumab inhibits IL-17A and prevents it from binding to its receptor.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Korman NJ, Zhao Y, Pike J, et al. Relationship between psoriasis severity, clinical symptoms, quality of life and work productivity among patients in the USA. Clin Exp Dermatol 2016; 41: 514–521. - PubMed
    1. Kirby B, Richards HL, Mason DL, et al. Alcohol consumption and psychological distress in patients with psoriasis. Br J Dermatol 2008; 158: 138–140. - PubMed
    1. Abuabara K, Azfar RS, Shin DB, et al. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol 2010; 163: 586–592. - PMC - PubMed
    1. Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55: 829–835. - PubMed
    1. Najarian DJ, Gottlieb AB. Connections between psoriasis and Crohn’s disease. J Am Acad Dermatol 2003; 48: 805–821; quiz 22–24. - PubMed
-